Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26552915 | 0.78 | — | — | |
| SCHEMBL41726 | 0.78 | — | — | |
| SCHEMBL10317295 | 0.76 | — | — | |
| SCHEMBL10319555 | 0.76 | — | — | |
| SCHEMBL48410 | 0.74 | MEN1 (0.42) | CA12CA2CA14CA3CA4 | |
| SCHEMBL293641 | 0.74 | CA2 (0.48) | CA12CA2CA14CA1CA3 | |
| SCHEMBL24393015 | 0.72 | PRMT3 (0.46) | CA12CA2CA14CA1ALDH1A1 | |
| SCHEMBL24393060 | 0.72 | CA2 (0.52) | CA12CA2CA14CA1CA3 | |
| SCHEMBL24393024 | 0.72 | CA1 (0.36) | CA12CA2CA14CA1CA7 | |
| SCHEMBL291781 | 0.72 | CA2 (0.46) | CA12CA2CA14CA1CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| WO-2022091048-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | disclosed |
| WO-2020035464-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
| US-8722883-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2014-05-13 | — | — | US | disclosed |
| EP-1809624-B1 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-11-20 | — | — | EP | disclosed |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA R&D ALDERLY PARK (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8410123-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-8269002-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2012-06-21 | — | — | US | disclosed |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2311827-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators. | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301933-A1 | Thiopyrimidine derivative, useful as an intermediate for chemokine receptor modulators | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-7838675-B2 | Pyrimidine sulphonamide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2006024823-A9 | PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194923-A1 | NOVEL SULFONAMIDEUREA COMPOUNDS | NLRP3, NOD1, NLRP1 | CA12 3374/4885CA2 1434/4885CA14 3642/4885 |
| US-20120157431-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CA12 3896/4885CA2 3334/4885CA14 3544/4885 |
| US-20110124619-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CA12 3896/4885CA2 3334/4885CA14 3544/4885 |
| US-20130203991-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CA12 3896/4885CA2 3334/4885CA14 3544/4885 |
| US-20080096860-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CA12 3855/4885CA2 3317/4885CA14 3495/4885 |
| US-20130012490-A1 | Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators | CXCR1, CCR5, ACKR3 | CA12 3855/4885CA2 3317/4885CA14 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.